CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company’s commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
1998
643
LTM Revenue $335M
LTM EBITDA $24.5M
$991M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CareDx has a last 12-month revenue of $335M and a last 12-month EBITDA of $24.5M.
In the most recent fiscal year, CareDx achieved revenue of $280M and an EBITDA of -$84.9M.
CareDx expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See CareDx valuation multiples based on analyst estimatesFY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $322M | $280M | $331M | $335M | XXX |
Gross Profit | $199M | $210M | $178M | XXX | XXX |
Gross Margin | 62% | 75% | 54% | XXX | XXX |
EBITDA | -$61.2M | -$84.9M | $23.6M | $24.5M | XXX |
EBITDA Margin | -19% | -30% | 7% | 7% | XXX |
Net Profit | -$30.7M | -$76.6M | -$190M | XXX | XXX |
Net Margin | -10% | -27% | -57% | XXX | XXX |
Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 7, 2025, CareDx's stock price is $22.
CareDx has current market cap of $1.2B, and EV of $991M.
See CareDx trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$991M | $1.2B | XXX | XXX | XXX | XXX | $-0.85 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 7, 2025, CareDx has market cap of $1.2B and EV of $991M.
CareDx's trades at 3.0x LTM EV/Revenue multiple, and 40.4x LTM EBITDA.
Analysts estimate CareDx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for CareDx and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $991M | XXX | XXX | XXX |
EV/Revenue | 3.0x | XXX | XXX | XXX |
EV/EBITDA | 42.0x | XXX | XXX | XXX |
P/E | -25.3x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCareDx's NTM/LTM revenue growth is 12%
CareDx's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, CareDx's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate CareDx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for CareDx and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 18% | XXX | XXX | XXX | XXX |
EBITDA Margin | 7% | XXX | XXX | XXX | XXX |
EBITDA Growth | -128% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | 19% | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | 30% | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 42% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 29% | XXX | XXX | XXX | XXX |
Opex to Revenue | 101% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
ToolGen | XXX | XXX | XXX | XXX | XXX | XXX |
4basebio | XXX | XXX | XXX | XXX | XXX | XXX |
Genus | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CareDx acquired XXX companies to date.
Last acquisition by CareDx was XXXXXXXX, XXXXX XXXXX XXXXXX . CareDx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was CareDx founded? | CareDx was founded in 1998. |
Where is CareDx headquartered? | CareDx is headquartered in United States of America. |
How many employees does CareDx have? | As of today, CareDx has 643 employees. |
Who is the CEO of CareDx? | CareDx's CEO is Mr. John Walter Hanna, Jr. |
Is CareDx publicy listed? | Yes, CareDx is a public company listed on NAS. |
What is the stock symbol of CareDx? | CareDx trades under CDNA ticker. |
When did CareDx go public? | CareDx went public in 2014. |
Who are competitors of CareDx? | Similar companies to CareDx include e.g. EZZ Life Science, ToolGen, 4basebio, Genus. |
What is the current market cap of CareDx? | CareDx's current market cap is $1.2B |
What is the current revenue of CareDx? | CareDx's last 12-month revenue is $335M. |
What is the current EBITDA of CareDx? | CareDx's last 12-month EBITDA is $24.5M. |
What is the current EV/Revenue multiple of CareDx? | Current revenue multiple of CareDx is 3.0x. |
What is the current EV/EBITDA multiple of CareDx? | Current EBITDA multiple of CareDx is 40.4x. |
What is the current revenue growth of CareDx? | CareDx revenue growth between 2023 and 2024 was 18%. |
Is CareDx profitable? | Yes, CareDx is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.